Similar articles

• Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.

  Truog AW, Wozniak SP. Truog AW, et al. Oncol Nurs Forum. 1990 Jan-Feb;17(1):39-44. Oncol Nurs Forum. 1990. PMID: 2405360 Review.
• Prevention of graft versus host disease following allogeneic bone marrow transplantation.

  Powles RL, Goss GD, Millar J, Maitland J, Borthwick-Clark C, Al-Jundi A. Powles RL, et al. Tokai J Exp Clin Med. 1985 Jun;10(2-3):133-8. Tokai J Exp Clin Med. 1985. PMID: 3914738 No abstract available.
• A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.

  Biggs JC, Atkinson K, Gillett E, Downs K, Concannon A, Dodds A. Biggs JC, et al. Transplant Proc. 1986 Apr;18(2):253-5. Transplant Proc. 1986. PMID: 3515659 Clinical Trial. No abstract available.
• Decreased incidence of graft-versus-host disease in bone marrow transplantation recipients treated with a combination of cyclosporine and methotrexate.

  Tollemar J, Ringdén O, Sundberg B, Bolme P, Brattström C, Gahrton G, Johansen L, Lönnqvist B. Tollemar J, et al. Transplant Proc. 1988 Jun;20(3):494-8. Transplant Proc. 1988. PMID: 3381257 No abstract available.
• Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.

  Schwinghammer TL, Bloom EJ. Schwinghammer TL, et al. Clin Pharm. 1993 Oct;12(10):736-61. Clin Pharm. 1993. PMID: 8258255 Review.